Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LJM716 + alpelisib + trastuzumab
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of LJM716 (anti-HER3 monoclonal antibody), alpelisib (BYL719, PI3K inhibitor), and trastuzumab (anti-HER2 monoclonal antibody). This triple combination targets multiple aspects of HER family signaling pathways in HER2-overexpressing cancers. LJM716 binds to HER3 and traps it in an inactive conformation, preventing heterodimer formation with other HER family receptors. Alpelisib is a PI3K inhibitor that targets downstream signaling. Trastuzumab binds to the extracellular domain of HER2, blocking receptor signaling and inducing antibody-dependent cell-mediated cytotoxicity.
- Other names
- BYL719 + LJM716 + trastuzumab
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on LJM716 + alpelisib + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LJM716 + alpelisib + trastuzumab.